Literature DB >> 16165914

Does electron and proton therapy reduce the risk of radiation induced cancer after spinal irradiation for childhood medulloblastoma? A comparative treatment planning study.

Xiangkui Mu1, Thomas Björk-Eriksson, Simeon Nill, Uwe Oelfke, Karl-Axel Johansson, Giovanna Gagliardi, Lennart Johansson, Mikael Karlsson, Dr Björn Zackrisson.   

Abstract

The aim of this treatment planning comparison study was to explore different spinal irradiation techniques with respect to the risk of late side-effects, particularly radiation-induced cancer. The radiotherapy techniques compared were conventional photon therapy, intensity modulated x-ray therapy (IMXT), conventional electron therapy, intensity/energy modulated electron therapy (IMET) and proton therapy (IMPT).CT images for radiotherapy use from five children, median age 8 and diagnosed with medulloblastoma, were selected for this study. Target volumes and organs at risk were defined in 3-D. Treatment plans using conventional photon therapy, IMXT, conventional electron therapy, IMET and IMPT were set up. The probability of normal tissue complication (NTCP) and the risk of cancer induction were calculated using models with parameters-sets taken from published data for the general population; dose data were taken from dose volume histograms (DVH). Similar dose distributions in the targets were achieved with all techniques but the absorbed doses in the organs-at-risk varied significantly between the different techniques. The NTCP models based on available data predicted very low probabilities for side-effects in all cases. However, the effective mean doses outside the target volumes, and thus the predicted risk of cancer induction, varied significantly between the techniques. The highest lifetime risk of secondary cancers was estimated for IMXT (30%). The lowest risk was found with IMPT (4%). The risks associated with conventional photon therapy, electron therapy and IMET were 20%, 21% and 15%, respectively. This model study shows that spinal irradiation of young children with photon and electron techniques results in a substantial risk of radiation-induced secondary cancers. Multiple beam IMXT seems to be associated with a particularly high risk of secondary cancer induction. To minimise this risk, IMPT should be the treatment of choice. If proton therapy is not available, advanced electron therapy may provide a better alternative.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16165914     DOI: 10.1080/02841860500218819

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  34 in total

1.  Predicted risks of second malignant neoplasm incidence and mortality due to secondary neutrons in a girl and boy receiving proton craniospinal irradiation.

Authors:  Phillip J Taddei; Anita Mahajan; Dragan Mirkovic; Rui Zhang; Annelise Giebeler; David Kornguth; Mark Harvey; Shiao Woo; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2010-11-12       Impact factor: 3.609

2.  An infant with prenatally diagnosed congenital anaplastic astrocytoma who remains disease-free after proton therapy.

Authors:  Hyun Jung Shin; Young Joo Kwon; Hyeon Jin Park; Byung Kiu Park; Sang Hoon Shin; Joo-Young Kim; Sang Hyun Lee; Heung Sik Kim; Dong Won Kim
Journal:  J Korean Med Sci       Date:  2013-08-28       Impact factor: 2.153

3.  A comparative study on the risks of radiogenic second cancers and cardiac mortality in a set of pediatric medulloblastoma patients treated with photon or proton craniospinal irradiation.

Authors:  Rui Zhang; Rebecca M Howell; Phillip J Taddei; Annelise Giebeler; Anita Mahajan; Wayne D Newhauser
Journal:  Radiother Oncol       Date:  2014-08-12       Impact factor: 6.280

4.  Low- and middle-income countries can reduce risks of subsequent neoplasms by referring pediatric craniospinal cases to centralized proton treatment centers.

Authors:  Phillip J Taddei; Nabil Khater; Bassem Youssef; Rebecca M Howell; Wassim Jalbout; Rui Zhang; Fady B Geara; Annelise Giebeler; Anita Mahajan; Dragan Mirkovic; Wayne D Newhauser
Journal:  Biomed Phys Eng Express       Date:  2018-02-07

5.  The evolution of proton beam therapy: Current and future status.

Authors:  Xiufang Tian; Kun Liu; Yong Hou; Jian Cheng; Jiandong Zhang
Journal:  Mol Clin Oncol       Date:  2017-11-14

6.  Comparison of risk of radiogenic second cancer following photon and proton craniospinal irradiation for a pediatric medulloblastoma patient.

Authors:  Rui Zhang; Rebecca M Howell; Annelise Giebeler; Phillip J Taddei; Anita Mahajan; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2013-01-16       Impact factor: 3.609

7.  Risk-optimized proton therapy to minimize radiogenic second cancers.

Authors:  Laura A Rechner; John G Eley; Rebecca M Howell; Rui Zhang; Dragan Mirkovic; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2015-04-28       Impact factor: 3.609

8.  Analytical model for out-of-field dose in photon craniospinal irradiation.

Authors:  Phillip J Taddei; Wassim Jalbout; Rebecca M Howell; Nabil Khater; Fady Geara; Kenneth Homann; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2013-10-08       Impact factor: 3.609

9.  Technical considerations for noncoplanar proton-beam therapy of patients with tumors proximal to the optic nerve.

Authors:  Masashi Mizumoto; Hidetsugu Nakayama; Mari Tokita; Shinji Sugahara; Haruko Hashii; Takeji Sakae; Koji Tsuboi; Hideyuki Sakurai; Koichi Tokuuye
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

10.  A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931).

Authors:  Jeffrey Allen; Bernadine Donahue; Minesh Mehta; Douglas C Miller; Lucy B Rorke; Regina Jakacki; Patricia Robertson; Richard Sposto; Emi Holmes; Gilbert Vezina; Karin Muraszko; Diane Puccetti; Michael Prados; Ka-Wah Chan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-07       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.